Buying guide
Best vagus nerve stimulator for HRV, and what the research really shows
HRV is the number this entire category is sold on. It is also the claim with the weakest support in it. Here is the evidence first, then what is still worth buying.
The short answer
A meta-analysis of 16 single blind studies found strong statistical evidence for the null: acute transcutaneous stimulation did not change vagally mediated heart rate variability in healthy people compared with sham.
What that leaves. The Parasym ear clip, sold as Nurosym or Nuropod, is the one device with a controlled autonomic result behind it: a sham controlled trial in postural tachycardia syndrome found the postural heart rate rise significantly lower than sham after two months.
Disclosure: Vagus Lab may earn a commission if you buy through links on this page. It does not change how we score devices. Our method is published and applied the same way to devices we have no commercial relationship with.
The finding that should change what you expect
A living Bayesian meta-analysis published in Psychophysiology pooled 16 single blind studies asking whether transcutaneous auricular stimulation alters vagally mediated heart rate variability. It did not find a small effect or an inconclusive one. It found strong statistical support for the null hypothesis.
That is unusual and worth stating plainly, because most negative results in a young field look like uncertainty. This one looks like an answer.
It is also a specific answer, and the specifics matter. Being precise about them is not a hedge, it is the difference between a useful finding and a slogan.
What the null result covers, and what it does not
It covers acute effects. Stimulation applied, HRV measured around the session. It does not cover what happens after six weeks of daily use.
It covers healthy participants. People whose autonomic function is already within normal range have less room to move, which is a recurring pattern across this kind of research.
It does not cover clinical populations. The one controlled trial in a diagnosed condition, in postural tachycardia syndrome, did find a significant autonomic difference against sham after two months.
The honest reading: if you are healthy and expecting a session to nudge tomorrow morning's readiness score, the evidence says no. If you have a diagnosed autonomic problem and are looking at months of daily use, that question is still open and one device has a result in it.
What is still worth buying, and on what grounds
Ranked on autonomic evidence rather than on marketing. Two of the four entries below are here on company published data or on measurement convenience, and the cards say so.
1. Nurosym, sold as Nuropod in the US
$900The only device with a controlled autonomic result
Why it is here: A sham controlled randomized trial in postural tachycardia syndrome, published in JACC Clinical Electrophysiology, found the postural heart rate rise significantly lower than sham after two months, and it names the Parasym device in its methods. That is an autonomic outcome, in a clinical population, over months, which is exactly the territory the discouraging HRV finding does not cover.
Watch out: The trial was 12 active against 14 sham, so it is small, and postural heart rate response is not the same measure as resting HRV. Thirty to sixty minutes a day, at the highest price in the category.
2. Hoolest VeRelief Prime
$199The only device publishing an HRV figure of its own
Why it is here: Its research page reports a 31 percent increase in heart rate variability among 24 patients with panic disorder or PTSD, alongside a 24 percent reduction in anxiety. It is the cheapest device here and runs without an app.
Watch out: That study is small and published by the company rather than in an indexed journal, so it carries much less weight than a peer reviewed trial. Handheld and one side at a time.
3. Apollo Neuro
$448Best if you want to actually watch the number
Why it is here: It integrates with the Oura Ring, so your stimulation and your overnight measurements sit in the same picture rather than in two apps you compare by hand. Four indexed publications name the device.
Watch out: Vibrotactile rather than electrical, so none of the vagus nerve stimulation literature applies to it, and none of its published studies establish an HRV effect.
4. Pulsetto
$259Best low cost way to run a proper trial on yourself
Why it is here: If you are going to test this over weeks rather than sessions, which is the only test worth running, do it on the device that costs least to find out with. Four to twenty minute sessions, worn hands free, $259 with free shipping.
Watch out: No indexed publication names Pulsetto and it publishes no HRV data of its own. You would be measuring with your own wearable, not with anything the device provides.
Why this order is different from our overall ranking
On the hub, price and convenience carry real weight. Here they mostly do not, because the question is narrower: what does anything published actually show about autonomic effects.
That puts the most expensive device first, on the strength of one small controlled trial, and it puts our lowest cost pick last with an explicit note that it is there as the cheapest way to run a fair test on yourself rather than on any evidence of its own.
If you are going to test it, test it properly
Day to day HRV moves with alcohol, illness, training load, sleep timing and the temperature of your bedroom. Any effect you are looking for here is smaller than that noise.
Which means a fair test looks like several weeks of daily use, compared against several weeks of your own prior baseline, not a session against the next morning's number. Change one thing at a time, and expect the honest answer to be "hard to tell", because that is what the pooled data says most people find.
Our full read of the evidence covers the outcomes where the research is more encouraging than this one.
Frequently asked questions
Not acutely in healthy people, on the best available evidence. A living Bayesian meta-analysis of 16 single blind studies found strong statistical support for the null hypothesis: transcutaneous stimulation did not alter vagally mediated heart rate variability compared with sham. HRV improvement is the most marketed claim in this category and it has the weakest support of anything we cover.